Shortened 8 Weeks Course of Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients, with Chronic Hepatitis C Infection.

Citation:
El-Shabrawi, M., A. M. Abdo, H. El-Khayat, and M. Yakoot, "Shortened 8 Weeks Course of Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients, with Chronic Hepatitis C Infection.", Journal of Pediatric Gastroenterology and Nutrition, vol. 66, issue 3, pp. 425-427, 2017 Nov 10, 2018.

Abstract:

Recently, sofosbuvir and the fixed dose combination of sofosbuvir/ ledipasvir were approved for the treatment of chronic hepatitis C virus infection (HCV) in adolescents, 12 years old and above or weighing at least 35 kilograms. Here we present the results of a pilot single cohort of 10 consecutive adolescent patients with chronic HCV and treated with dual sofosbuvir/daclatasvir (SOF/DCV) therapy for a response-tailored duration of 8 weeks for those who achieved very rapid virologic response (vRVR) and 12 weeks for those who did not. All patients achieved vRVR at week 2 and completed the shortened 8 weeks course. All patients (10/10 (100% (CI: 72.25-100%)) achieved sustained virologic response at week 12 post-treatment (SVR12) with good tolerability and no serious adverse events. This data could provide support to our suggested response-tailored protocol of dual therapy with SOF/DCV in adolescents particularly for shortened duration in those who achieved vRVR. Further larger randomized controlled studies are recommended.